Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial

CC Zielinski1,2, B Schnack1, M Grbovic1, T Brodowicz1, C Wiltschke1, G Steger2, H Pflüger4 and M Marberger2

1Chair for Medical Experimental Oncology and Ludwig Boltzmann Institute for Clinical Experimental Oncology; 2Clinical Division of Oncology, Department of Medicine I; 3Department of Urology, University Hospital; 4Department of Urology, Hospital of Lainz, Vienna, Austria

Summary The present phase II trial was undertaken to assess the efficacy and toxicity of a combination of paclitaxel and carboplatin as first-line chemotherapy in patients with metastatic transitional cell carcinoma of the urothelium. Twenty patients (age range 50–79 years; inclusion criteria: WHO performance status 0–2, no previous cytotoxic treatment) with metastatic transitional cell carcinoma of the urothelium were recruited and received cytotoxic treatment with paclitaxel at a dosage of 175 mg m⁻² administered over a 3-h infusion and carboplatin given at an AUC of 5 mg ml⁻¹ min (according to creatinine clearance) administered every 21 days. A total of 65% of patients achieved remissions (CR+PR), with CR occurring in 40% of patients. A further 15% of patients experienced stable disease. Remissions occurred after 2.4 ± 0.8 (mean ± standard deviation; range two to four) treatment cycles. The mean duration of responses (CR+PR) was 8.5 ± 5.5 months. After a mean observation period of 11.4 ± 4.8 months, 16 patients (80%) are alive. Toxicity included alopecia of WHO grade 3 in all patients, leucopenia of WHO grades 1 and 2 in ten patients, grade 3 in eight and grade 4 in two patients and, finally, severe thrombocytopenia grade 3 in only three patients. Non-haematological toxicity consisted of polyneuropathy of WHO grade 1 in 13 patients and grade 2 in five patients. We thus conclude that a combination of paclitaxel and carboplatin at the given dosage and schedule constitutes an active, well-tolerated first-line cytotoxic treatment for patients with metastatic urothelial cancer.

Keywords: urothelial cancer; paclitaxel; carboplatin

Treatment of metastatic cancer of transitional cells of the urothelium by cytotoxic chemotherapy has led to marked improvement in the prognosis of patients suffering from this disease. Before the development of effective chemotherapy, survival of patients with metastatic urothelial cancer rarely exceeded 3–6 months. In contrast, combination chemotherapy has significantly improved survival rates by inducing remissions in over 70% of patients (Harker et al. 1985; Sternberg et al. 1985; Logothetis et al. 1990c). Although a series of combinations of cytotoxic drugs has been studied, treatment with methotrexate, vinblastine, doxorubicin and cyclophosphamide (cisplatin) (M-VAC) has become therapy of choice because of its favourable efficacy (Sternberg et al. 1988, 1989; Loehrer et al. 1992), ever since its development at Memorial Sloan-Kettering Cancer Center in 1983 (Sternberg et al. 1985). Although cisplatin is thought to be the most active agent of this combination, M-VAC was found to be superior over single-agent therapy with this drug (Loehrer et al. 1992). However, the administration of M-VAC can produce a series of side-effects, including myelosuppression, sepsis, mucositis, peripheral neuropathy and nephrotoxicity (Loehrer et al. 1992). Among others, it is mainly nephrotoxicity that prevents the inclusion of many, in particular elderly, patients with advanced urothelial cancer who often have decreased renal function under this treatment protocol. Several modifications of the standard M-VAC regimen have been proposed, including the substitution of epirubicin for doxorubicin to reduce cardiotoxicity or of carboplatin for cisplatin (Petroli et al. 1996) to reduce nephrotoxicity. Moreover, attempts have been made to replace cisplatin by gallium nitrate under the addition of vinblastine and ifosfamide (Einhorn et al. 1994).

The advent of newer cytotoxic drugs has changed the scenario in advanced urothelial cancer, as significant single-drug activity has been reported not only for carboplatin (Mottet-Auselo et al. 1995) but also for agents such as paclitaxel (Roth et al. 1994) as well as gemcitabine (Pollera et al. 1994; Stadler et al. 1997; von der Maase et al. 1997). Confronted with the limitations and toxicities of M-VAC chemotherapy outlined above and based upon earlier studies that have demonstrated impressive single-agent efficacy of paclitaxel leading to an objective response rate of 42% (Roth et al. 1994) and good efficacy of carboplatin accompanied by simultaneous low toxicity (Waxman and Barton. 1993) in patients with urothelial cancer, the present investigation was undertaken. The treatment protocol of the present phase II trial involved the combined administration of paclitaxel and carboplatin in patients with advanced urothelial cancer and resulted in a response rate (CR+PR) of 65% with relatively low concomitant toxicity.

PATIENTS AND METHODS

Patients

The study was initiated in June 1995 and conducted according to the declaration of Helsinki, after having been approved by the ethical committee of the Medical Faculty and the University Hospital. The study included 20 patients (12 women, eight men) with a mean age of 67 (range 50–79) years suffering from
metastatic, histologically verified pure transitional cell carcinoma of the urothelium. Nine patients were older than 70 years, which was permitted by the protocol that concerned recruitment up to the age of 79 years (see below). Locations of metastatic disease included lymph nodes (13 patients), liver (three patients), lung (four patients) and the skeleton (two patients). Also included were patients in whom lung metastases occurred simultaneously with metastases to lymph nodes, in one case, and simultaneously with liver metastases, in another. Characteristics of patients are given in Table 1.

None of the patients was pretreated by cytotoxic chemotherapy for any stage of the disease, and all patients were eligible for the study and evaluable for efficacy and toxicity of the chosen therapeutic protocol. The current report covers a mean observation period of 11.4 ± 4.8 months.

Inclusion criteria

Inclusion criteria consisted of histologically verified carcinoma of the urothelium at the time of diagnosis. Metastases to lymph nodes and/or inner organs verified by biopsy and/or computed tomography (CT), performance status WHO 0–1 (Karnofsky ≥ 60), age 18–79 years, creatinine clearance ≥ 30 ml min⁻¹ and a signed patient consent to participate in the study.

Exclusion criteria

Exclusion criteria included: previous treatment of the current disease with cytotoxic chemotherapy; local disease only; inadequate haematological function (as defined by white blood cells < 3.5 × 10⁹ l⁻¹, granulocytes < 1.5 × 10⁹ l⁻¹, platelets < 100 × 10⁹ l⁻¹); the staging procedure being carried out more than 2 weeks before onset of chemotherapy; second malignancy with the exception of in situ cervix cancer or adequately treated basal cell or squamous cell carcinoma of the skin; history of atrial or ventricular arrhythmias and/or history of congestive heart failure (even if medically controlled); history of clinical and electrocardiographically documented myocardial infarction; and pre-existing motor or sensory neurotoxicity > grade 1, according to WHO criteria (severe paraesthesia and/or mild weakness or worse). Finally, other exclusion criteria included: active infection or any other serious underlying medical condition that would impair the ability of the patient to receive protocol treatment; altered mental status that would prohibit the understanding and giving of informed consent; pregnancy and breast feeding; severe hepatic dysfunction (bilirubin and/or transaminases ≥ 1.25 x upper limits of normal); and creatinine clearance <30 ml min⁻¹.

Cytotoxic therapy

Dose and schedule

Paclitaxel (175 mg m⁻² body surface) was given by a 3-h continuous infusion subsequently followed by carboplatin given at an AUC of 5 mg ml⁻¹ min according to creatinine clearance on day 1 of a 21-day cycle. This combination has been shown to be safe in previous investigations (Spencer et al. 1994).

Supportive therapy

Antianaphylactic drug therapy consisting of cimetidine, diphenhydramine and dexamethasone was given before taxol treatment, and standard antiemetic medication was administered.

*Table 1 Patients' characteristics

| Characteristics          | Number of patients |
|--------------------------|--------------------|
| Age (years)              |                    |
| < 69                     | 11                 |
| > 70                     | 9                  |
| Sex                      |                    |
| Male                     | 8                  |
| Female                   | 12                 |
| Performance status (WHO) |                    |
| 0                        | 10                 |
| 1                        | 10                 |
| Sites of metastases      |                    |
| Lymph nodes              | 13                 |
| Liver                    | 3                  |
| Lung                     | 4                  |
| Bones                    | 2                  |
| Multiple sites           | 2                  |

*Table 2 Responses in patients with metastases in different locations

| Location             | CR| PR| SD| PD |
|----------------------|---|---|---|----|
| Lymph nodes          | 7 | 3 | 2 |    |
| Liver                | 1 | - | - | 1  |
| Lung                 | - | 2 | - |    |
| Lung + lymph nodes   | - | 1 | - |    |
| Lung + liver         | - | - | - | 1  |
| Bones                | - | - | 1 |    |

*Number of patients achieving complete remission (CR), partial remission (PR), stable disease (SD) or experiencing progressive disease (PD).

*Table 3 Treatment-associated toxicity in 20 assessable patients

| WHO | I | II | III | IV |
|-----|---|----|-----|----|
| All patients | Leucopenia | 3  | 7  | 8  | 2  |
|        | Thrombocytopenia | 0  | 0  | 3  | 0  |
|        | Alopecia | 0  | 0  | 20 | 0  |
|        | Polyneuropathy | 13 | 5  | 0  | 0  |
| Patients > 70 years (n = 9) | Leucopenia | 1  | 3  | 4  | 1  |
|        | Thrombocytopenia | 0  | 0  | 2  | 0  |
|        | Alopecia | 0  | 0  | 9  | 0  |
|        | Polyneuropathy | 4  | 3  | 0  | 0  |

*All patients included in the trial were assessable for treatment-associated toxicity.

Evaluation of patients

Before treatment was started, patients were staged according to the TNM classification for urinary bladder cancer. The following procedures were furthermore performed: obligatory – physical examination, chest radiography, laboratory tests, sonography of the liver, total body bone scan. CT scan, intravenous pyelography: optional – barium enema/sigmoidoscopy, site-specific ultrasound. CT or magnetic resonance imaging, biopsy, urine cytology, bone

© Cancer Research Campaign 1998

British Journal of Cancer (1998) 78(3), 370–374
radiography in case of hot spots in total body bone scan. Responses and toxicities were assessed before each treatment cycle with chemotherapy being administered in 21-day intervals. Furthermore, a complete obligatory diagnostic work-up was performed every other treatment cycle.

**Duration of therapy**

After the documentation of clinical complete remission (CR), two additional cycles of cytotoxic chemotherapy were administered. In case of stable disease (SD) or partial remission (PR), a total of six cycles were given. Documented progression of disease according to WHO criteria resulted in discontinuation of the treatment protocol.

**Statistical analysis**

Data are given as mean ± standard deviation. Statistical calculation were carried out using the log-rank test (overall survival) or chi-square test (toxicity), both performed with the BMDP-PC program package using a level of significance of 0.05.

**RESULTS**

**Response to treatment**

After a mean follow-up of 11.4 ± 4.8 months, 8 (40%) out of 20 patients have achieved complete remission (CR) and five (25%) partial remission (PR), resulting in an overall response rate (CR + PR) of 65%. Moreover, three patients (15%) have experienced stable disease (SD). The remaining four patients (20%) had progressive disease despite the treatment. The mean number of treatments needed to achieve responses was 2.4 ± 0.8 (range two to four). No difference in the number of treatment cycles needed to achieve responses was found between patients with CR (2.4 ± 0.7) and PR (2.4 ± 0.8). The mean number of treatment cycles administered was 5.8 ± 0.7 (range 4–6) in patients with CR and 4.4 ± 0.9 (range 3–6) in patients with PR. The duration of responses was 8.5 ± 5.5 (range 1.1–14.9) months in patients with CR and 7.1 ± 4.2 (range 2.3–11.7) months in patients with PR. Figure 1 shows a Kaplan–Meier plot for recurrence or progression of disease. In a detailed analysis, no significant difference in overall survival was found between patients < 69 (9 of 11 patients alive) and > 70 years (seven of nine patients alive; P > 0.05) and, interestingly, between patients with various responses to treatment (CR: seven of eight patients alive; PR: four of five patients alive; P > 0.05).

**Response according to location of metastases**

Table 2 shows the rate of responses in dependence upon the location of metastases. It is noteworthy that 10 out of 12 patients with exclusively lymph node metastases achieved response (CR + PR).

**Treatment-associated toxicity**

Treatment-associated toxicity including polyneuropathy, leucopenia and thrombopenia was generally low. The only exception was alopecia grade 3 (WHO), which was experienced in all 20 patients. A detailed description of toxicities is given in Table 3. Low treatment-associated toxicity was also observed in nine patients >70 years who were also analysed separately (Table 3) and in whom the frequency and severity of side-effects did not differ significantly from that in younger patients (P > 0.05 respectively).

**Duration of remissions and survival**

After a mean observation period of 11.4 ± 4.8 (range 4–17) months, 16 out of 20 patients (80%) are alive, whereas the remaining four patients have died as a result of progressive carcinoma. Thus, 82.5% of patients have experienced an overall survival of 9.1 months (Figure 1). Seven patients have remained in CR for a mean duration of 9.1 (range 1.3–14.9) months, including one patient with liver metastases (Table 2) whose duration of CR is 7.5 months at the time of preparation of the manuscript.

**DISCUSSION**

Cytotoxic treatment consisting of a combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) has proved to represent effective treatment for metastatic urothelial cancer by primarily leading to responses in 72% (36% CR) of 121 assessable patients (Sternberg et al. 1989). In further trials, responses were observed in 42–57% (CR 13–19%) of patients (Chong et al. 1987; Hillcoat et al. 1989; Tannock et al. 1989; Igawa et al. 1990; Bouthan-Laroze et al. 1991). An intergroup phase III study resulted in a response rate of 39% (CR 13%) of patients whose median survival was 12.5 months (Loehrer et al. 1992). This latter trial also addressed the question of the importance of single-agent toxicity with cisplatin (70 mg m⁻² body surface), which has been discussed to be mainly responsible for the good efficacy of the entire regimen. However, responses achieved in the cisplatin arm were only 12% (CR 3%; Loehrer et al. 1992). Further attempts to increase the efficacy of M-VAC by an increase in dose intensity through the inclusion of colony-stimulating factors were unsuccessful (Logothetis et al. 1990b; Seidman et al. 1993). Although remaining the treatment of choice in patients with advanced urothelial cancer, M-VAC is hampered by, at times, high toxicity (Sternberg et al. 1989; Logothetis et al. 1990b; Loehrer et al. 1992). Thus, with the introduction of newer cytostatic drugs, including gemcitabine and paclitaxel, the possibility of increasing efficacy with low concomitant treatment-associated toxicity had to be re-examined (Pollera et al. 1994; Roth et al. 1994). Setting out from the concept that the antimitotribular agent paclitaxel, which had proved to be effective in a series of tumours in vivo (Ozols, 1995) and against human bladder tumour cell lines in vitro (Rangel et al. 1994), an Eastern Cooperative Oncology Group trial tested for the efficacy of paclitaxel administered to 26 patients with metastatic urothelial cancer in a dose of 250 mg m⁻² over 24 h
Roth et al. 1994). Responses reached 42% (CR 27%, PR 15%), and cytotoxic treatment was relatively well tolerated; however, because of the high dose of paclitaxel, the protocol had to include ranulocyte colony-stimulating factor. In an attempt to further mitigate these findings, while trying to keep toxicity low in a population of patients with metastatic urothelial cancer, because of epidemiological reasons often consists of elderly persons with reduced organ function as a result of advanced age, we have tested for the efficacy and toxicity of a combination of aclarixal in a lower dose under the addition of carboplatin, which as also been shown to exert single-agent activity in advanced relaistic cancer (Mottet-Auseloo et al. 1995). The present study is not a prognostic factor in the present analysis, as the response to treatment was identical in patients < 69 and > 70 years. Comparing our previous base trials of single-agent paclitaxel (Roth et al. 1994), the study was higher in 65% vs 42%, with a higher frequency of CRs (40% vs. 27%) in populations of patients similar in number (20 vs 26), thus suggesting that the results obtained in the present trial were most probably not related to the diminution of paclitaxel alone. M-VAC polychemotherapy has been shown to produce frequent treatment-associated side-effects, including myelotoxicity in 76%, nephrotoxicity (grades 3 and 4) in 17% and polyneuropathy in 5% of 126 patients Loehrer et al. 1992). In contrast, in the present trial, myelotoxicity was infrequent and severe polyneuropathy of grades 3 or 4 was not encountered. It is important to stress that patients over the age of 0 years did not experience significantly increased toxicity compared with younger patients, thus making the protocol also applicable for an older patient population with advanced urothelial cancer. We thus conclude that a combination of paclitaxel and carboplatin constitutes effective treatment of advanced urothelial cancer and is well tolerated.

Acknowledgements

The trial was supported in part by a grant from Bristol-Myers Squibb Company. The authors are grateful to Ms Smrek-Markusfeld for typing the manuscript.

References

Roth JL, Drijer IR, Bosl GW, Lipperman MJ, Roth FD, Dornhofer R, Greco F, Kerbrat P, Cay A. Vossein PM, Spielmann M, Rey A and Girard B 1991 M-VAC: methotrexate, vinblastine, doxorubicin and cisplatin for advanced carcinoma of the bladder. Eur J Cancer 27: 1690–1694

Chong C, Logothetis CJ, Dexeus FH and Sella A 1987 M-VAC as salvage chemotherapy in transitional cell carcinoma of the urothelium previously treated with cisplatin combination chemotherapy. Proc Am Soc Clin Oncol 28: 810

Emhoorn LH, Roth BJ, Ansart R, Drijer IR, Groen R and Loehrer PJ 1994 Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271–2276

Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF. McWhirter KM and Tori FM 1985 Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3: 1463–1470

Hillside BL, Raghavan D, Matthew J, Kefford R, Yuen K, Woods R, Oliver L, Bishop J, Pearson B and Cookey G 1989 A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelium. J Clin Oncol 7: 706–709

Igawa M, Ohtsuki T, Ueki T, Ueda M, Okada K and Ushio T 1990 usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662–665

Loehrer PJ, Emhoorn LH, Elson PJ, Crawford ED, Kuebler P, Tannick L. Raghavan D, Stuart-Harris R, Sarodos MF, Low BS, Blumenstein B and Trump D 1992 A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066–1073

Logothetis CJ, Dexeus FH, Fenn L, Sella A, Amato JT, Ayala AG and Kilbourn RG 1990 A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J Clin Oncol 8: 1050–1055

Logothetis CJ, Dexeus FH, Sella A, Amato JT, Kilbourn RG, Fenn L and Guttermann JL 1990b Escalated therapy for refractory, urothelial tumours: methotrexate–vinblastine–doxorubicin–cisplatin plus uroelycosylated recombinant human granulocyte-macrophage colony-stimulating factor. J Urol Cancer Inst 82: 667–672

Mottet-Auseloo N, Bons-Rosset F, Pellaar-Cosset B, Costa P, Schwartz Y, Louis JF and Navaratil H 1995 Carboplatin and urothelial tumours: an overview. Bull Cancer 82: 181–188

Ozols RF 1995 The emerging role of paclitaxel in cancer chemotherapy. Semin Oncol 22 (suppl. 6): 1–131

Petrolli R, Frediani B, Manganeli A, Barbanti G, De Capua B, De Lauretis A, Salvestrini F, Mondillo S and Franceschi G 1996: Comparison between a cisplatin-containing regimen and a cisplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer 77: 344–351

Pollera CF, Cerbelli A, Crecco M and Calabresi F 1994 Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182–184

Rangel C, Niell H, Miller A and Cox C 1994 Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33: 460–464

Roth BJ, Drijer IR, Emhoorn LH, Neuberger D, Johnson DH, Smith JH, Hudes GR, Schultz SM and Loehrer PJ 1994 Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264–2270

Seidman AD, Scher HI, Gabriole J, Bajorski D, Motzer RJ, O’Dell M, Curley T, Dershow DW, Quinlivan S, Tao Y, Fair WR, Begg C and Bowl GI 1993: Dose-intensification of M-VAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 11: 408–414

Spencer CM and Foulds D 1994 Paclitaxel – a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48: 794–847

Stadler WM, Murphy B, Kaufman D, Raghavan D and Voi M 1997 Phase II trial of gemcitabine plus cisplatin in metastatic urothelial cancer. Proc Am Soc Clin Oncol 16: 1152

Stemberg CN, Yogada A, Scher HI, Watson RC, Ahmed T, Weisberg LR, Geller N, Holland PS, Herr HW, Sogani PC, Morse MJ and Whitmore WF 1985 Preliminary results of M-VAC methotrexate, vinblastine, doxorubicin and cisplatin for transitional cell carcinoma of the urothelium. J Urol 133: 403–407

Stemberg CN, Yogada A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weisberg LR, Geller N, Holland PS, Lipperman L, Flatt WR and Whitmore WF 1988 M-VAC Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461–464

Cancer Research Campaign 1998

British Journal of Cancer (1998) 78(3), 370–374

32
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64: 2448–2458

Tannock I, Gospodarowicz M, Connolly J and Jewett M (1989) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142: 289–292

Von der Maase H, Andersen L, Crino L, Weissbach L and Dogliotti L (1997) A phase II study of gemcitabine and cisplatin in patients with transitional carcinoma of the urothelium. Proc Am Soc Clin Oncol 16: 1155

Waxman J and Barton C (1993) Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19 (suppl. C): 21–25